Mersana Therapeutics Inc.

NASDAQ: MRSN · Real-Time Price · USD
7.37
0.21 (2.93%)
At close: Aug 18, 2025, 3:59 PM
7.24
-1.76%
After-hours: Aug 18, 2025, 06:39 PM EDT

Mersana Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
40.5M 36.85M 26.58M 43K
Cost of Revenue
1.63M 148.27M 927K 132.01M
Gross Profit
38.87M -111.41M 25.65M -131.97M
Operating Income
-73.34M -170.96M -204.69M -169.71M
Interest Income
8.44M 12.07M 2.88M 65K
Pretax Income
-68.77M -171.67M -204.21M -170.06M
Net Income
-69.19M -171.67M -207.54M -169.21M
Selling & General & Admin
40.81M 59.54M 56.96M 36.89M
Research & Development
73.02M 148.27M 173.38M 132.01M
Other Expenses
n/a n/a -445K -1.2M
Operating Expenses
113.83M 36.85M 230.35M 168.9M
Interest Expense
3.87M 4.07M 3.33M 1.27M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
113.83M 207.81M 230.35M 168.9M
Income Tax Expense
418K n/a 3.33M -855K
Shares Outstanding (Basic)
4.9M 4.64M 3.75M 2.82M
Shares Outstanding (Diluted)
4.9M 4.64M 3.75M 2.82M
EPS (Basic)
-14.12 -36.96 -54.51 -60.24
EPS (Diluted)
-14.12 -36.96 -54.51 -60.24
EBITDA
-63.27M -166.08M -199.96M -167.94M
EBIT
-64.9M -167.6M -200.88M -168.79M
Depreciation & Amortization
1.63M 1.52M 927K 855K